<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1647">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04393311</url>
  </required_header>
  <id_info>
    <org_study_id>56639</org_study_id>
    <nct_id>NCT04393311</nct_id>
  </id_info>
  <brief_title>Ulinastatin for the Treatment of COVID-19 in Hospitalized Patients</brief_title>
  <official_title>A Multi-Center, Randomized, Double-Blind, Placebo Controlled Study of the Safety and Efficacy of Ulinastatin for the Treatment of COVID-19 in Hospitalized Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to evaluate the safety and efficacy of intravenous&#xD;
      (IV) infusion of ulinastatin compared to placebo with respect to time to recovery, disease&#xD;
      severity, need for ventilator support, and mortality in patients with COVID 19.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 2021</start_date>
  <completion_date type="Anticipated">August 2021</completion_date>
  <primary_completion_date type="Anticipated">August 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to recovery</measure>
    <time_frame>Up to 29 days</time_frame>
    <description>Time to recovery, defined as attaining a score of 6, 7, or 8 on the COVID-19 disease severity scale, an 8 point ordinal scale used in the NIH Adaptive COVID-19 Treatment Trial (ACTT; NCT04280705).&#xD;
= Death;&#xD;
= Hospitalized and on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO);&#xD;
= Hospitalized and on non-invasive ventilation or high-flow oxygen devices;&#xD;
= Hospitalized and requiring supplemental oxygen;&#xD;
= Hospitalized and not requiring supplemental oxygen but requiring ongoing medical care (COVID-19-related or otherwise);&#xD;
= Hospitalized and not requiring supplemental oxygen and no longer requiring ongoing medical care;&#xD;
= Not hospitalized, limitation on activities and/or requiring home oxygen;&#xD;
= Not hospitalized, no limitation on activities</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>COVID-19 disease severity scale score on Day 8</measure>
    <time_frame>Day 8</time_frame>
    <description>COVID-19 disease severity scale (range; 1-8, higher scores correspond to better health state).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>COVID-19 disease severity scale score on Day 15</measure>
    <time_frame>Day 15</time_frame>
    <description>COVID-19 disease severity scale (range; 1-8, higher scores correspond to better health state).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>COVID-19 disease severity scale score on Day 22</measure>
    <time_frame>Day 22</time_frame>
    <description>COVID-19 disease severity scale (range; 1-8, higher scores correspond to better health state).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>COVID-19 disease severity scale score on Day 29</measure>
    <time_frame>Day 29</time_frame>
    <description>COVID-19 disease severity scale (range; 1-8, higher scores correspond to better health state).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of mortality at Day 29</measure>
    <time_frame>29 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of in-hospital mortality</measure>
    <time_frame>Up to 29 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days alive and not on mechanical ventilator or ECMO in the 28 days following first dose</measure>
    <time_frame>Up to 29 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with resolution of symptoms defined as score of 8 on the 8-point ordinal scale at Day 29</measure>
    <time_frame>Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients alive and free of respiratory failure defined as score of 4, 5, 6, 7, or 8 on the 8-point ordinal scale at Day 29</measure>
    <time_frame>Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of mechanical ventilation</measure>
    <time_frame>Up to 29 days</time_frame>
    <description>For patients requiring mechanical ventilation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of ECMO</measure>
    <time_frame>Up to 29 days</time_frame>
    <description>For patients requiring mechanical ECMO.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of noninvasive ventilation</measure>
    <time_frame>Up to 29 days</time_frame>
    <description>For patients requiring non-invasive ventilation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of ICU stay</measure>
    <time_frame>Up to 29 days</time_frame>
    <description>For patients admitted to ICU</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of hospital stay</measure>
    <time_frame>Up to 29 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in oxygen saturation</measure>
    <time_frame>Between screening and 24 hours after last dose (up to 6 days)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>Ulinastatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive ulinastatin via IV infusion every 8 hours for up to 5 days or until hospital discharge (whichever is earlier).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients will receive placebo to match ulinastatin via IV infusion every 8 hours for up to 5 days or until hospital discharge (whichever is earlier).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ulinastatin</intervention_name>
    <description>Ulinastatin administered via IV infusion (200,000/infusion)</description>
    <arm_group_label>Ulinastatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo to match ulinastatin administered via IV infusion</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Willing and able to provide written informed consent&#xD;
&#xD;
          -  Signs and symptoms suggestive of COVID-19 infection&#xD;
&#xD;
          -  Laboratory-confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)&#xD;
             infection ≤7 days before randomization&#xD;
&#xD;
          -  Currently hospitalized or in an emergency department with planned hospitalization&#xD;
&#xD;
          -  Peripheral capillary oxygen saturation (SpO2) &lt;93% on room air at Screening&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Simultaneous participation in any other clinical study incompatible with this one&#xD;
&#xD;
          -  Treatment with an antibody immunotherapy within 4 weeks of Screening&#xD;
&#xD;
          -  Requirement for mechanical ventilation or ECMO at Screening&#xD;
&#xD;
          -  Hypotension at Screening&#xD;
&#xD;
          -  Severe liver injury defined as AST or ALT ≥5x the upper limit of normal&#xD;
&#xD;
          -  Severe kidney failure defined as an estimated glomerular filtration rate (eGFR) &lt;30&#xD;
             mL/min&#xD;
&#xD;
          -  Pregnancy or breastfeeding&#xD;
&#xD;
          -  &gt; 120 hours between admission and signing consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kevin V Grimes, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>May 15, 2020</study_first_submitted>
  <study_first_submitted_qc>May 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 19, 2020</study_first_posted>
  <last_update_submitted>January 14, 2021</last_update_submitted>
  <last_update_submitted_qc>January 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinastatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>No plan to share data.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

